United States: Updates On Aflibercept BPCIA Litigation - Goodwin Procter LLP
The proposed schedule also provides dates for document discovery and depositions.
Full Article
United States: Updates On Aflibercept BPCIA Litigation - Goodwin Procter LLP
Mondaq
0 shares
1 views
You might like
Related news coverage
United States: Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation - Goodwin Procter LLP
Mondaq
As we have previously reported, in November 2023 Regeneron Pharmaceuticals, Inc. ("Regeneron") filed complaints against Celltrion,..